BIOM UP SA overview

DGAP-News: Biom'up / Key word(s): Regulatory Approval Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia 07.10.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up announces the approval of HEMOBLAST TM Bellows and its laparoscopic applicator in Australia Successful review of HEMOBLAST Bellows' performance and safety profile as well as Biom'up's Quality Management System by the Australian Therapeutic Goods...

DGAP-News: Biom'up / Key word(s): Half Year Results Biom'up: Approval of 2019 H1 interim results postponed: Board of Directors pursues review of options available to the Company 30.09.2019 / 19:00 The issuer is solely responsible for the content of this announcement. Approval of 2019 H1 interim results postponed: Board of Directors pursues review of options available to the Company Estimated total sales of HEMOBLAST(TM) Bellows for the first nine months of 2019 are expected to show strong growth...

DGAP-News: Biom'up / Key word(s): Personnel Biom'up strengthens management team 18.09.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up strengthens management team Veteran MedTech executive Patrice Ferrand is appointed CEO Experienced pharmaceutical and biotech industry executive Evelyne Nguyen is appointed Group CFO Dr. Jan Ohrstrom continues his tenure as Chairman of the Board Current CCO for the United States George Makhoul is appointed CEO of Biom'up...

DGAP-News: Biom'up / Key word(s): Study Biom'up: New Publication Highlights Application of HEMOBLAST(TM) Bellows in Cardiovascular Surgery 14.08.2019 / 08:00 The issuer is solely responsible for the content of this announcement. New Publication Highlights Application of HEMOBLAST TM Bellows in Cardiovascular Surgery Article describes successful use and advantages of HEMOBLAST Bellows in high risk patients prone to bleeding undergoing cardiovascular surgical procedures. Saint-Priest, France,...

DGAP-News: Biom'up / Key word(s): Financing Biom'up issues a new tranche of EUR 5 million from the credit line granted by Athyrium 07.08.2019 / 18:00 The issuer is solely responsible for the content of this announcement. Biom'up issues a new tranche of EUR 5 million from the credit line granted by Athyrium Issue of bonds with warrants attached, fully subscribed by Athyrium within the framework of the EUR 35 million facility announced on April 3, 2018 A cash shortfall now estimated as of early...

DGAP-News: Biom'up / Key word(s): Half Year Results Biom'up Provides Business Update for the First Half of 2019 and confirms its Revenue Guidance for the year 10.07.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up Provides Business Update for the First Half of 2019 and confirms its Revenue Guidance for the year Global, unaudited sales of HEMOBLAST(TM) Bellows for the first half of 2019 were EUR1.4 million - on track to achieve 2019 revenue guidance...

DGAP-News: Biom'up / Key word(s): Personnel Industry Veteran Dr. Jan Ohrstrom takes on Executive Leadership of Biom'up 31.05.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Industry Veteran Dr. Jan Ohrstrom takes on Executive Leadership of Biom'up Saint-Priest, France, May 31, 2019 - 8h00 (CET) - Biom'up SA (the "Company "), specializing in surgical hemostasis, today announced a change in the Company's leadership position. Etienne Binant steps down from his...

DGAP-News: Biom'up / Key word(s): Conference Biom'up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City 20.05.2019 / 20:00 The issuer is solely responsible for the content of this announcement. Biom'up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City Saint-Priest, France, May 20, 2019 - 18h00 (CET) - Biom'up (the « Company »), specializing in surgical hemostasis, today announced...